מחיר ריאלי לרכישת החברה במלואה: TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD, Inc. (TXMD) relies on a patent-protected suite of hormonal treatments and strong relationships with B2B insurers. Management is currently transforming the business model, shifting toward the monetization of intellectual property rights to reduce debt. The historical price action of the Separate Enterprise Value is 17.09, while steady cash flow is ensured by licensing payments, which offsets the lack of new internal developments.

For the biopharmaceutical business of TherapeuticsMD, Inc. (TXMD), which is protected by patents in the women's health sector, the enterprise value history reflects the actual acquisition cost of the asset. This metric aggregates market capitalization and net debt, excluding cash from the valuation. Such a calculation determines the actual costs of buying out the company in its entirety. The indicator demonstrates the business's resilience in the face of generic competition. The trend of the curve helps investors assess whether the issuer is overvalued relative to its intellectual property rights.